Operaciones First Wave BioPharma, Inc. - FWBI CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.1324 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 0.001 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | 3.0292 |
| Abrir* | 2.9691 |
| Cambio de 1 año* | 180.1% |
| Rango del día* | 2.9691 - 3.1283 |
| Rango de 52 semanas | 2.76-289.80 |
| Volumen medio (10 días) | 117.79K |
| Volumen medio (3 meses) | 11.20M |
| Capitalización de mercado | 3.05M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 995.00K |
| Ingresos | N/A |
| EPS | -248.68 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 1.69 |
| Próxima fecha de resultados | N/A |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Mar 20, 2023 | 3.0588 | 0.0499 | 1.66% | 3.0089 | 3.1283 | 2.9691 |
| Mar 17, 2023 | 3.0291 | 0.0600 | 2.02% | 2.9691 | 3.0391 | 2.9591 |
| Mar 16, 2023 | 2.9695 | 0.1986 | 7.17% | 2.7709 | 3.0093 | 2.7704 |
| Mar 15, 2023 | 2.9302 | 0.1883 | 6.87% | 2.7419 | 2.9302 | 2.6917 |
| Mar 14, 2023 | 2.7715 | -0.1685 | -5.73% | 2.9400 | 2.9400 | 2.6912 |
| Mar 13, 2023 | 3.0191 | -0.5440 | -15.27% | 3.5631 | 3.5731 | 2.9982 |
| Mar 10, 2023 | 3.6238 | 0.0103 | 0.29% | 3.6135 | 3.6634 | 3.5640 |
| Mar 9, 2023 | 3.7131 | -0.2472 | -6.24% | 3.9603 | 4.1786 | 3.5639 |
| Mar 8, 2023 | 3.5246 | -0.0395 | -1.11% | 3.5641 | 3.6041 | 3.4648 |
| Mar 7, 2023 | 3.5148 | -0.0593 | -1.66% | 3.5741 | 3.7130 | 3.5047 |
| Mar 6, 2023 | 3.6437 | 0.0800 | 2.24% | 3.5637 | 3.7130 | 3.5637 |
| Mar 3, 2023 | 3.6436 | 0.1790 | 5.17% | 3.4646 | 3.7723 | 3.4646 |
| Mar 2, 2023 | 3.5146 | 0.0496 | 1.43% | 3.4650 | 3.5546 | 3.4650 |
| Mar 1, 2023 | 3.5346 | 0.0200 | 0.57% | 3.5146 | 3.5645 | 3.4650 |
| Feb 28, 2023 | 3.4750 | 0.1891 | 5.75% | 3.2859 | 3.5248 | 3.2856 |
| Feb 27, 2023 | 3.4157 | -0.2371 | -6.49% | 3.6528 | 3.7229 | 3.3658 |
| Feb 24, 2023 | 3.6733 | 0.0595 | 1.65% | 3.6138 | 3.7923 | 3.5241 |
| Feb 23, 2023 | 3.7228 | -0.0391 | -1.04% | 3.7619 | 3.7924 | 3.6632 |
| Feb 22, 2023 | 3.7724 | -0.2872 | -7.07% | 4.0596 | 4.1492 | 3.6723 |
| Feb 21, 2023 | 4.0894 | 0.3475 | 9.29% | 3.7419 | 4.2978 | 3.6622 |
First Wave BioPharma, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 6.32516 | 10.2212 | 13.4318 | 14.7437 | 26.8313 | 59.0569 |
| Gastos de venta/general/administración Gastos, total | 3.43886 | 6.93171 | 8.17431 | 6.04227 | 7.27976 | 18.3696 |
| Investigación y desarrollo | 2.49611 | 2.39548 | 4.98555 | 7.85849 | 19.105 | 38.3204 |
| Depreciation / Amortization | 0.6902 | 0.754 | 0.06191 | 0.84299 | 0.048 | 0.015 |
| Other Operating Expenses, Total | -0.3 | 0.14 | 0.21 | 0 | ||
| Ingresos de explotación | -6.32516 | -10.2212 | -13.4318 | -14.7437 | -26.8313 | -59.0569 |
| Ingresos por intereses (gastos), netos No operativos | -5.93749 | -0.8752 | -0.10185 | -0.43394 | -5.84013 | -0.01007 |
| Otros, netos | -2.32902 | 0 | 0.5291 | |||
| Ingresos netos antes de impuestos | -14.5917 | -11.0964 | -13.5336 | -15.1777 | -32.6715 | -58.5378 |
| Ingresos netos después de impuestos | -14.5917 | -11.0964 | -13.5336 | -15.1777 | -32.6715 | -58.5378 |
| Beneficio neto antes de partidas extra. Elementos | -14.5917 | -11.0964 | -13.5336 | -15.1777 | -32.6715 | -58.5378 |
| Ingresos netos | -14.5917 | -11.0964 | -13.5336 | -15.1777 | -32.6715 | -58.5378 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -14.5917 | -11.0964 | -13.5336 | -15.1777 | -41.7323 | -84.5186 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -14.5917 | -11.0964 | -13.5336 | -15.1777 | -41.7323 | -84.5186 |
| Beneficio neto diluido | -14.5917 | -11.0964 | -13.5336 | -15.1777 | -41.7323 | -84.5186 |
| Promedio ponderado de acciones diluidas | 0.65048 | 1.06288 | 1.54393 | 2.24256 | 2.84363 | 8.92573 |
| BPA diluido sin partidas extraordinarias | -22.4322 | -10.4399 | -8.76569 | -6.76803 | -14.6757 | -9.4691 |
| BPA normalizado diluido | -22.4322 | -10.4399 | -8.76569 | -6.76803 | -14.5356 | -9.20559 |
| Ingresos | 0 | |||||
| Gastos (ingresos) extraordinarios | 0.39857 | 2.35199 | ||||
| Total Adjustments to Net Income | -9.06087 | -25.9807 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 8.21354 | 9.27689 | 30.3995 | 11.167 | 9.38207 |
| Gastos de venta/general/administración Gastos, total | 5.69751 | 3.62809 | 6.02116 | 3.03678 | 4.40556 |
| Investigación y desarrollo | 2.51503 | 5.6468 | 24.3783 | 5.77821 | 4.97652 |
| Depreciation / Amortization | 0.001 | 0.002 | |||
| Ingresos de explotación | -8.21354 | -9.27689 | -30.3995 | -11.167 | -9.38207 |
| Ingresos por intereses (gastos), netos No operativos | -0.00474 | -0.00295 | -0.00074 | -0.00123 | -0.00547 |
| Otros, netos | 0.53265 | 0.0009 | -0.00057 | -0.00428 | -0.2393 |
| Ingresos netos antes de impuestos | -7.68563 | -9.27894 | -30.4008 | -11.1725 | -9.62684 |
| Ingresos netos después de impuestos | -7.68563 | -9.27894 | -30.4008 | -11.1725 | -9.62684 |
| Beneficio neto antes de partidas extra. Elementos | -7.68563 | -9.27894 | -30.4008 | -11.1725 | -9.62684 |
| Ingresos netos | -7.68563 | -9.27894 | -30.4008 | -11.1725 | -9.62684 |
| Total Adjustments to Net Income | -22.2956 | -3.45087 | -0.11809 | -0.11623 | -0.68577 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -29.9812 | -12.7298 | -30.5189 | -11.2887 | -10.3126 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -29.9812 | -12.7298 | -30.5189 | -11.2887 | -10.3126 |
| Beneficio neto diluido | -29.9812 | -12.7298 | -30.5189 | -11.2887 | -10.3126 |
| Promedio ponderado de acciones diluidas | 5.53481 | 7.81244 | 9.34236 | 12.9223 | 15.5447 |
| BPA diluido sin partidas extraordinarias | -5.41684 | -1.62943 | -3.26672 | -0.87359 | -0.66342 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -5.41684 | -1.62943 | -3.26672 | -0.69158 | -0.66342 |
| Gastos (ingresos) extraordinarios | 2.35199 |
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Activo Corriente | 2.96397 | 1.95257 | 4.8 | 3.40829 | 7.86978 | 9.42495 |
| Efectivo e inversiones a corto plazo | 1.77353 | 0.57347 | 1.11434 | 0.1758 | 6.06214 | 8.24868 |
| Cash | 1.77353 | 0.57347 | 1.11434 | 0.1758 | 6.06214 | 8.24868 |
| Inversiones a corto plazo | 0 | |||||
| Total deudores, neto | 0.96104 | 1.10413 | 3.17268 | 2.6373 | 0.55149 | 0 |
| Prepaid Expenses | 0.22941 | 0.27496 | 0.51298 | 0.59519 | 1.25615 | 1.17627 |
| Total Assets | 6.75384 | 5.47967 | 7.4694 | 8.90288 | 12.9239 | 11.79 |
| Property/Plant/Equipment, Total - Net | 0.15162 | 0.13399 | 0.12885 | 0.15978 | 0.09257 | 0.40931 |
| Goodwill, Net | 1.76755 | 2.01624 | 1.92483 | 1.88669 | 2.05405 | 1.91171 |
| Intangibles, Net | 1.83602 | 1.34596 | 0.57048 | 3.40708 | 2.87954 | 0 |
| Other Long Term Assets, Total | 0.03468 | 0.03092 | 0.04523 | 0.04105 | 0.02792 | 0.04401 |
| Total Current Liabilities | 2.34084 | 2.47908 | 2.99552 | 4.28564 | 15.5454 | 12.3004 |
| Payable/Accrued | 2.17846 | 2.05534 | 0.6701 | 0.53343 | 0 | |
| Accrued Expenses | 0.00719 | 0.00719 | 0.53829 | 0.15441 | 0.18443 | 0.49706 |
| Notes Payable/Short Term Debt | 0.15519 | 0.41655 | 0.25503 | 1.5213 | 0.55241 | 0.64124 |
| Other Current Liabilities, Total | 0 | 0.39299 | 13.25 | 8.48018 | ||
| Total Liabilities | 3.54084 | 3.81908 | 2.99552 | 4.28564 | 15.5646 | 19.6115 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 1.2 | 1.34 | 0 | 0 | 0.01912 | 7.31114 |
| Total Equity | 3.213 | 1.66059 | 4.47387 | 4.61724 | -2.64069 | -7.82155 |
| Common Stock | 0.00096 | 0.00121 | 0.00177 | 0.00268 | 0.00312 | 0.00149 |
| Additional Paid-In Capital | 27.561 | 37.6696 | 53.1393 | 68.5759 | 93.8349 | 147.305 |
| Retained Earnings (Accumulated Deficit) | -22.8871 | -33.9834 | -47.5171 | -62.6947 | -95.3662 | -153.904 |
| Other Equity, Total | -1.46188 | -2.02679 | -1.15011 | -1.26656 | -1.11255 | -1.22414 |
| Total Liabilities & Shareholders’ Equity | 6.75384 | 5.47967 | 7.4694 | 8.90288 | 12.9239 | 11.79 |
| Total Common Shares Outstanding | 0.96311 | 1.20426 | 1.77049 | 2.68005 | 3.11503 | 14.8559 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | |
| Property/Plant/Equipment, Total - Gross | 0.33225 | 0.4233 | 0.13097 | 0.42402 | ||
| Accumulated Depreciation, Total | -0.20339 | -0.26352 | -0.0384 | -0.01471 | ||
| Accounts Payable | 1.53211 | 1.68351 | 1.55859 | 2.68191 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 13.1704 | 8.61528 | 7.50249 | 9.42495 | 6.55017 |
| Efectivo e inversiones a corto plazo | 12.0256 | 8.07449 | 7.21065 | 8.24868 | 5.69499 |
| Cash | 12.0256 | 8.07449 | 7.21065 | 8.24868 | 5.69499 |
| Total deudores, neto | 0.50166 | 0 | 0 | 0 | 0.02806 |
| Prepaid Expenses | 0.64313 | 0.54079 | 0.29184 | 1.17627 | 0.82713 |
| Total Assets | 17.9829 | 13.7768 | 12.424 | 11.79 | 8.82544 |
| Property/Plant/Equipment, Total - Net | 0.06162 | 0.48488 | 0.44889 | 0.40931 | 0.3788 |
| Property/Plant/Equipment, Total - Gross | 0.0812 | 0.4861 | 0.45632 | 0.42402 | 0.40083 |
| Accumulated Depreciation, Total | -0.01958 | -0.00123 | -0.00743 | -0.01471 | -0.02203 |
| Goodwill, Net | 1.97396 | 1.99129 | 1.94474 | 1.91171 | 1.86207 |
| Intangibles, Net | 2.74765 | 2.61576 | 2.48388 | 0 | |
| Other Long Term Assets, Total | 0.02924 | 0.0696 | 0.04403 | 0.04401 | 0.0344 |
| Total Current Liabilities | 3.57464 | 6.45412 | 19.0983 | 12.3004 | 14.2157 |
| Accounts Payable | 1.44072 | 4.44991 | 18.4478 | 2.68191 | 3.44993 |
| Accrued Expenses | 0.32383 | 0.31246 | 0.22987 | 0.49706 | 0.7883 |
| Notes Payable/Short Term Debt | 0.34708 | 0.13957 | 0 | 0.64124 | 0.40277 |
| Other Current Liabilities, Total | 1.46302 | 1.55218 | 0.42063 | 8.48018 | 9.57473 |
| Total Liabilities | 3.58121 | 6.73988 | 19.394 | 19.6115 | 18.0652 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.00657 | 0.28575 | 0.29569 | 7.31114 | 3.8495 |
| Total Equity | 14.4017 | 7.03692 | -6.96999 | -7.82155 | -9.23979 |
| Common Stock | 0.00749 | 0.00826 | 0.00111 | 0.00149 | 0.00215 |
| Additional Paid-In Capital | 118.693 | 120.585 | 137.028 | 147.305 | 155.571 |
| Retained Earnings (Accumulated Deficit) | -103.052 | -112.331 | -142.732 | -153.904 | -163.531 |
| Other Equity, Total | -1.24734 | -1.2255 | -1.26711 | -1.22414 | -1.28254 |
| Total Liabilities & Shareholders’ Equity | 17.9829 | 13.7768 | 12.424 | 11.79 | 8.82544 |
| Total Common Shares Outstanding | 7.49269 | 8.25851 | 11.1152 | 14.8559 | 21.5488 |
| Preferred Stock - Non Redeemable, Net | 0 |
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -14.5917 | -11.0964 | -13.5336 | -15.1777 | -32.6715 | -58.5378 |
| Efectivo de actividades de explotación | -4.53486 | -7.18464 | -10.8693 | -14.0335 | -11.2215 | -32.2882 |
| Efectivo de actividades de explotación | 0.04431 | 0.04952 | 0.06191 | 0.0631 | 0.0378 | 0.01471 |
| Amortization | 0.6902 | 0.70448 | 0.73654 | 0.95695 | 0.52755 | 0.52755 |
| Partidas no monetarias | 8.61743 | 3.42595 | 3.57765 | 1.82513 | 6.73365 | 8.60641 |
| Cambios en el capital circulante | 0.70487 | -0.26821 | -1.7118 | -1.70099 | 14.1509 | 17.101 |
| Efectivo de actividades de inversión | -0.01236 | -0.03217 | -0.30547 | -0.0241 | 0.08735 | -10.3195 |
| Gastos de capital | -0.01236 | -0.03217 | -0.30547 | -0.0241 | -0.00417 | -0.06949 |
| Efectivo procedente de actividades de financiación | 5.74629 | 6.01322 | 11.7121 | 13.145 | 17.0461 | 44.7635 |
| Elementos de flujo de caja de financiación | -1.42011 | 0 | ||||
| Emisión (retiro) de acciones, neto | 5.28 | 5.00923 | 11.9028 | 9.53834 | 14.1861 | 44.6747 |
| Emisión (amortización) de deuda, neta | 1.8864 | 1.00399 | -0.19068 | 3.60664 | 2.86003 | 0.08883 |
| Efectos del cambio de divisas | -0.00722 | 0.00353 | 0.00354 | -0.02593 | -0.02559 | 0.03076 |
| Variación neta de la tesorería | 1.19186 | -1.20005 | 0.54087 | -0.93855 | 5.88635 | 2.18654 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | ||
| Intereses pagados en efectivo | 0.00415 | 0.00401 | 0.00803 | 0.10546 | 0 | |
| Otras partidas de flujo de caja de inversión, total | 0.09152 | -10.25 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.68563 | -16.9646 | -47.3654 | -58.5378 | -9.62684 |
| Cash From Operating Activities | -5.07339 | -10.6961 | -26.4254 | -32.2882 | -7.91207 |
| Cash From Operating Activities | 0.00102 | 0.00301 | 0.00939 | 0.01471 | 0.00732 |
| Amortization | 0.13189 | 0.26377 | 0.39566 | 0.52755 | 0 |
| Non-Cash Items | 1.80638 | 1.7359 | 2.04186 | 8.60641 | 0.36042 |
| Cash Interest Paid | 0.00514 | 0 | 0 | 0 | 0 |
| Changes in Working Capital | 0.67294 | 4.26576 | 18.493 | 17.101 | 1.34703 |
| Cash From Investing Activities | 0 | -9.07393 | -10.3215 | -10.3195 | |
| Capital Expenditures | 0 | -0.07393 | -0.07145 | -0.06949 | |
| Cash From Financing Activities | 11.0506 | 21.8326 | 37.9406 | 44.7635 | 5.36715 |
| Financing Cash Flow Items | -9.53235 | -2.41496 | |||
| Issuance (Retirement) of Stock, Net | 20.7883 | 22.2454 | 38.493 | 44.6747 | 8.02057 |
| Issuance (Retirement) of Debt, Net | -0.20532 | -0.41284 | -0.55241 | 0.08883 | -0.23847 |
| Foreign Exchange Effects | -0.01374 | -0.05019 | -0.04525 | 0.03076 | -0.00877 |
| Net Change in Cash | 5.96349 | 2.01235 | 1.1485 | 2.18654 | -2.5537 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Other Investing Cash Flow Items, Total | -9 | -10.25 | -10.25 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Sapirstein (James E) | Individual Investor | 4.3072 | 42857 | 42857 | 2023-01-03 | HIGH |
| Armistice Capital LLC | Hedge Fund | 4.2206 | 41995 | 41995 | 2022-12-31 | HIGH |
| Romano (Sarah M.) | Individual Investor | 2.1537 | 21429 | 21429 | 2023-01-03 | MED |
| Hoffman (David Andrew) | Individual Investor | 1.3033 | 12968 | 12106 | 2023-01-03 | HIGH |
| Borkowski (Edward J) | Individual Investor | 1.237 | 12308 | 12106 | 2023-01-03 | |
| Riddell (Alastair) | Individual Investor | 1.223 | 12169 | 12106 | 2023-01-03 | |
| Casamento (Charles J) | Individual Investor | 1.2223 | 12162 | 12106 | 2023-01-03 | |
| Coelho (Mary Theresa) | Individual Investor | 1.2167 | 12106 | 12106 | 2023-01-03 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.1858 | 11799 | 0 | 2022-12-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.7214 | 7178 | 7178 | 2022-12-31 | MED |
| Susquehanna International Group, LLP | Investment Advisor | 0.2193 | 2182 | 2182 | 2022-12-31 | MED |
| UBS Financial Services, Inc. | Investment Advisor | 0.2048 | 2038 | 1752 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1537 | 1529 | 1529 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.0982 | 977 | 0 | 2023-02-28 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0975 | 970 | 497 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0379 | 377 | 0 | 2022-12-31 | LOW |
| Advisor Group, Inc | Investment Advisor | 0.0287 | 286 | 286 | 2022-12-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.0027 | 27 | 0 | 2022-12-31 | LOW |
| U.S. Bancorp Asset Management, Inc. | Investment Advisor | 0.0024 | 24 | 0 | 2022-12-31 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.0022 | 22 | 0 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group 500000+
Traders
92000+
Clientes activos mensualmente
$53000000+
Volumen mensual de inversión
$30000000+
Pruébalo ahora Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
First Wave BioPharma, Inc. Company profile
Sobre First Wave BioPharma Inc
First Wave BioPharma, Inc, anteriormente AzurRx BioPharma, Inc, es una empresa biofarmacéutica en fase clínica. Se dedica al desarrollo de terapias no sistémicas dirigidas a enfermedades gastrointestinales (GI). Se centra en el avance de una línea de desarrollo terapéutico construida en torno a sus dos tecnologías: la niclosamida, una pequeña molécula oral con propiedades antivirales y antiinflamatorias, y la adrulipasa biológica, una enzima lipasa recombinante diseñada para permitir la digestión de las grasas y otros nutrientes. La cartera de niclosamidas de la empresa está encabezada por tres programas clínicos: FW-COV, para las infecciones gastrointestinales por COVID-19; FW-UP, para la proctitis ulcerosa (UP) y la proctosigmoiditis ulcerosa; y FW-ICI-AC, para la colitis y la diarrea asociadas a los inhibidores del punto de control inmunitario de grado 1 y grado 2 en pacientes oncológicos avanzados. También está avanzando FW-EPI (adrulipasa) para el tratamiento de la insuficiencia pancreática exocrina (IPE) en pacientes con fibrosis quística y pancreatitis crónica.
| Industry: | Biotechnology & Medical Research (NEC) |
777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com